Skip to main content

Gastroenterology vs Metabolic — Deal Terms Comparison

Gastroenterology Median Upfront
$529M
Total: $2.7B
Metabolic Median Upfront
$935M
Total: $4.5B
Gastroenterology Royalties
7.7%-14.2%
Tiered to 18.2%
Metabolic Royalties
16.1%-29.5%
Tiered to 33.5%

Market Analysis

Gastroenterology and Metabolic represent distinct licensing landscapes with different risk-reward dynamics. Phase 2 gastroenterology deals carry a median total deal value of $2.7B with $529M upfront, compared to $4.5B total value and $935M upfront for metabolic. The differences reflect divergent clinical development timelines, regulatory pathways, and addressable market sizes.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

or
Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How do gastroenterology and metabolic deal terms compare?
Gastroenterology Phase 2 deals average $2.7B total value ($529M upfront), while Metabolic deals average $4.5B ($935M upfront). The differences are driven by addressable market size, clinical development complexity, and regulatory pathway characteristics.
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

or
Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating